"Artificial intelligence": Which services, which applications, which results and which development today in clinical research? Which impact on the quality of care? Which recommendations?

Vincent Diebolt, Isaac Azancot, François-Henri Boissel, Isabelle Adenot, Christine Balagué (), Philippe Barthelemy, Nacer Boubenna, Hélène Coulonjou, Xosé Fernandez, Enguerrand Habran, Françoise Lethiec, Juliette Longin, Anne Metzinger, Yvon Merlière, Emmanuel Pham, Pierre Philip (), Thomas Roche, William Saurin (), Anny Tirel, Emannuelle Voisin and Thierry Marchal
Additional contact information
Vincent Diebolt: Plateforme F-CRIN - UT3 - Université Toulouse III - Paul Sabatier - UT - Université de Toulouse - CHU Toulouse - Centre Hospitalier Universitaire de Toulouse - INSERM - Institut National de la Santé et de la Recherche Médicale
Isaac Azancot: Hôpital Lariboisière - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Lariboisière-Fernand-Widal [APHP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - UPD7 - Université Paris Diderot - Paris 7
François-Henri Boissel: Novadiscovery [Lyon]
Isabelle Adenot: HAS - Haute Autorité de Santé [Saint-Denis La Plaine]
Christine Balagué: IMT-BS - MMS - Département Management, Marketing et Stratégie - TEM - Télécom Ecole de Management - IMT - Institut Mines-Télécom [Paris] - IMT-BS - Institut Mines-Télécom Business School - IMT - Institut Mines-Télécom [Paris], LITEM - Laboratoire en Innovation, Technologies, Economie et Management (EA 7363) - UEVE - Université d'Évry-Val-d'Essonne - IMT-BS - Institut Mines-Télécom Business School - IMT - Institut Mines-Télécom [Paris]
Philippe Barthelemy: AstraZeneca
Nacer Boubenna: Inserm-Transfert [Paris] - INSERM - Institut National de la Santé et de la Recherche Médicale
Hélène Coulonjou: DRCI - Délégation de la Recherche Clinique et de l’Innovation [Paris] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
Xosé Fernandez: Institut Curie [Paris]
Enguerrand Habran: Fédération Hospitalière de France (FHF)
Françoise Lethiec: Janssen-Cilag [Issy-les-Moulineaux]
Juliette Longin: Merck Santé - Merck & Co. Inc - Merck Sharp and Dohme
Anne Metzinger: HCL - Hospices Civils de Lyon
Yvon Merlière: Caisse nationale d'assurance maladie des travailleurs salariés [CNAMTS]
Emmanuel Pham: IPSEN - IPSEN Research Laboratories
Pierre Philip: CHU de Bordeaux Pellegrin [Bordeaux]
Thomas Roche: DELSOL Avocats (.)
William Saurin: Dassault Systèmes
Anny Tirel: MSD
Emannuelle Voisin: VCLS - Voisin Consulting Life Sciences (.)
Thierry Marchal: UCL - Université Catholique de Louvain = Catholic University of Louvain

Post-Print from HAL

Abstract: Artificial intelligence (AI), beyond the concrete applications that have already become part of our daily lives, makes it possible to process numerous and heterogeneous data and knowledge, and to understand potentially complex and abstract rules in a manner human intelligence can but without human intervention. AI combines two properties, self-learning by the successive and repetitive processing of data as well as the capacity to adapt, that is to say the possibility for a scripted program to deal with multiple situations likely to vary over time. Roundtable experts confirmed the potential contribution and theoretical benefit of AI in clinical research and in improving the efficiency of patient care. Experts also measured, as is the case for any new process that people need to get accustomed to, its impact on practices and mindset. To maximize the benefits of AI, four critical points have been identified. The careful consideration of these four points conditions the technical integration and the appropriation by all actors of the life science spectrum: researchers, regulators, drug developers, care establishments, medical practitioners and, above all, patients and the civil society. 1st critical point: produce tangible demonstrations of the contributions of AI in clinical research by quantifying its benefits. 2nd critical point: build trust to foster dissemination and acceptability of AI in healthcare thanks to an adapted regulatory framework. 3rd critical point: ensure the availability of technical skills, which implies an investment in training, the attractiveness of the health sector relative to tech-heavy sectors and the development of ergonomic data collection tools for all health operators. 4th critical point: organize a system of governance for a distributed and secure model at the national level to aggregate the information and services existing at the local level. Thirty-seven concrete recommendations have been formulated which should pave the way for a widespread adoption of AI in clinical research. In this context, the French "Health data hub" initiative constitutes an ideal opportunity.

Keywords: Interoperability; Governance; Artificial Intelligence; Interdisciplinary; Training; Data; Knowledge; Clinical research; Clinical trials; Real-life studies; Assessment (search for similar items in EconPapers)
Date: 2019-02
Note: View the original document on HAL open archive server: https://hal.science/hal-02053243v1
References: View complete reference list from CitEc
Citations:

Published in Thérapie, 2019, 74 (1), pp.155 - 164. ⟨10.1016/j.therap.2018.12.003⟩

Downloads: (external link)
https://hal.science/hal-02053243v1/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-02053243

DOI: 10.1016/j.therap.2018.12.003

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().